Moreover, in a metanalysis comparing anthracycline-based adjuvant regimens with non – anthracycline based (including CMF like regimen) in women with early-stage breast cancer was provided evidence of an interaction between HER2 status and responsiveness to adjuvant anthracyclines with no benefit from adjuvant anthracyclines regimens in patients with HER2-negative disease, raising the issue for a better selection of patients that could be benefit from non-anthracycline adjuvant regimens [17]. The gene discussed is ERBB2; the disease is breast carcinoma.